More patients achieved complete resolution of anterior chamber cells with LOTEMAX® Ointment vs vehicle at Day 8 following cataract surgery1,2
More patients treated with LOTEMAX® Ointment were pain-free vs vehicle at Day 8 following cataract surgery1,2
- In 2 Phase 3 studies, LOTEMAX® Ointment demonstrated a significantly higher rate of complete clearing of anterior chamber cells and flare* at postoperative Day 8 vs vehicle (24%-32% vs 11%-14%; P<0.0001)1,2,†
- Significantly more patients were pain free at postoperative Day 8 vs vehicle (73%-78% vs 41%-45%; P<0.0001)1,2,†
A TOLERABILITY PROFILE YOU EXPECT FROM LOTEPREDNOL ETABONATE2
Low incidence of significant intraocular pressure (IOP) elevations2
- Only 3 of 404 patients treated with LOTEMAX® Ointment and 1 of 401 patients treated with vehicle had an elevation of IOP ≥10 mm Hg over the course of the study†
- If this product is used for 10 days or longer, IOP should be monitored.
*Cell count 0 and no flare.
†Study design: Two randomized, multicenter, double-masked, parallel-group, vehicle-controlled studies in 805 subjects with a combined grade of ≥3 for anterior chamber cells and flare 1 day after uncomplicated cataract surgery.